Pharmacological conversion of persistent atrial fibrillation into sinus rhythm with oral pilsicainide - Pilsicainide suppression trial for persistent atrial fibrillation II

Circulation Journal

Volumn 70, Issue 6, 2006, Pages 657-661

  Okishige, Kaoru ^a   Fukunami, Masatake ^b   Kumagai, Koichiro ^c   Atarashi, Hirotsugu ^d   Inoue, Hiroshi ^e  

^a YOKOHAMA CITY MINATO RED CROSS HOSPITAL   (Japan)

^b OSAKA GENERAL MEDICAL CENTER   (Japan)

^c FUKUOKA UNIVERSITY HOSPITAL   (Japan)

^d NIPPON MEDICAL SCHOOL TAMA NAGAYAMA HOSPITAL   (Japan)

^e UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Cardioversion; Persistent atrial fibrillation; Pilsicainide; Randomized clinical trial

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; PILSICAINIDE; WARFARIN;

ADULT; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CARDIOVERSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFIBRILLATION; DRUG EFFICACY; DRUG SAFETY; ELECTROCARDIOGRAM; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART ATRIUM THROMBOSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; SINUS RHYTHM; TRANSESOPHAGEAL ECHOCARDIOGRAPHY;

ADMINISTRATION, ORAL; ADULT; AGED; ANTI-ARRHYTHMIA AGENTS; ANTICOAGULANTS; ATRIAL FIBRILLATION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LIDOCAINE; MALE; MIDDLE AGED; RECOVERY OF FUNCTION; REMISSION INDUCTION; THROMBOSIS; WARFARIN;

EID: 33744472207     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.70.657     Document Type: Article

References (30)

1. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort study: The Framingham Heart Study. JAMA 1994; 271: 840-844.
2. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: Incidence, risk factors, and prognosis in the Manitoba Follow-up Study. Am J Med 1995; 98: 476-484.
3. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation: Analysis and implications. Arch Intern Med 1995; 155: 469-473.
4. Carlsson J, Miketic S, Windeler J, Cuneo A, Haun S, Micus S, et al for the STAF Investigators. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: The Strategies of Treatment of Atrial Fibrillation (STAF) Study. J Am Coll Cardiol 2003; 41: 1690-1696.
5. The AFFIRM Investigators. Relationship between sinus rhythm, treatment, and survival in the atrial fibrillation follow-up investigation of rhythm management (AFFIRM) study. Circulation 2004; 109: 1509-1513.
6. Stroobandt R, Stiels B, Hoebrechts R, on behalf of the Propafenone Atrial Fibrillation Trial Investigators. Propafenone for conversion and prophylaxis of atrial fibrillation. Am J Cardiol 1997; 79: 418-423.
7. Kuhlkamp V, Schmid F, Risler T, Seipel L. Randomized comparison of flecainide and cibenzoline in the conversion of atrial fibrillation. Int J Cardiol 1991; 31: 65-69.
8. Donovan KD, Dobb GJ, Coombs LJ, Lee KY, Weekes JN, Murdock CJ, et al. Efficacy of flecainide for the reversion of acute onset atrial fibrillation. Am J Cardiol 1992; 70: A50-A55.
9. Hohnloser SH, van de Loo A, Baedeker F. Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: Prospective comparison of sotalol versus quinidine. J Am Coll Cardiol 1995; 26: 852-858.
10. Singh S, Zoble RG, Yellen L, Brodsky MA, Feld GK, Berk M, et al for the Dofetilide Atrial Fibrillation Investigators. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: The Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) Study. Circulation 2000; 102: 2385-2390.
11. Channer KS, Birchall A, Steeds RP, Walters SJ, Yeo WW, West JN, et al. A randomized placebo-controlled trial of pre-treatment and short- or long-term maintenance therapy with amiodarone supporting DC cardioversion for persistent atrial fibrillation. Eur Heart J 2004; 25: 144-150.
12. Hattori Y, Hidaka T, Aisaka K, Satoh F, Ishihara T. Effect of SUN 1165, a new potent antiarrhythmic agent, on the kinetics of the rate-dependent block of Na channel and ventricular conduction of extrasystoles. J Cardiovasc Pharmacol 1988; 11: 407-412.
13. Kodama I, Ogawa S, Inoue H, Kasanuki H, Kato T, Mitamura H, et al. The Guideline Committee for Clinical Use of Antiarrhythmic Drugs in Japan: Profiles of aprindine, cibenzoline, pilsicainide and pirmenol in the framework of the Sicilian Gambit. Jpn Circ J 1999; 63: 1-12.
14. Atarashi H, Inoue H, Hiejima K, Hayakawa H, for the PSTAF Investigators. Conversion of recent-onset atrial fibrillation by a single oral dose of pilsicainide (Pilsicainide Suppression Trial on Atrial Fibrillation). Am J Cardiol 1996; 78: 694-697.
15. Kumagai K, Abe H, Hiraki T, Nakashima H, Oginosawa Y, Ikeda H, et al. Single oral administration of pilsicainide versus infusion of disopyramide for termination of paroxysmal atrial fibrillation. Pacing Clin Electrophysiol 2000; 23: 1880-1882.
16. Okishige K, Nishizaki M, Azegami K, Igawa M, Yamawaki N, Aonuma K. Pilsicainide for conversion and maintenance of sinus rhythm in chronic atrial fibrillation: A placebo-controlled, multicenter study. Am Heart J 2000; 140: 437-444.
17. Yasaka M, Minematsu K, Yamaguchi T. Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fibrillation. Intern Med 2001; 40: 1183-1188.
18. Nozawa T, Inoue H, Iwasa A, Okumura K, Jong-dae L, Shimizu A, et al. Effects of anticoagulation intensity on hemostatic markers in patients with non-valvular atrial fibrillation. Circ J 2004; 68: 29-34.
19. Tielman RG, Gosselink ATM, Crijns HJGM, van Gelder IC, van den berg MP, de Kam PJ, et al. Efficacy, safety, and determinants of conversion of atrial fibrillation and flutter with oral amiodarone. Am J Cardiol 1997; 79: 53-57.
20. Kochiadakis GEK, Igoumenidis NE, Solomou MC, Kaleboubas MD, Chlouverakis GI, Vardas PE. Efficacy of amiodarone for the termination of persistent atrial fibrillation. Am J Cardiol 1999; 83: 58-61.
21. Torp-Pedersen C, Moller M, Kober L, Camm AJ. Dofetilide for the treatment of atrial fibrillation in patients with congestive heart failure. Eur Heart J 2000; 21: 1204-1206.
22. Prystowsky EN, Freeland S, Branyas NA, Rardon DP, Fogel RI, Padanilam BJ, et al. Clinical experience with dofetilide in the treatment of patients with atrial fibrillation. J Cardiovasc Electrophysiol 2003; 14: S287-S290.
23. Fujiki A, Tsuneda T, Sakabe M, Nakagawa K, Mizumaki K, Hirai T, et al. Maintenance of sinus rhythm and recovery of atrial mechanical function after cardioversion with bepridil or in combination with aprindine in long-lasting persistent atrial fibrillation. Circ J 2004; 68: 834-839.
24. Reisinger J, Gatterer E, Heinze G, Wiesinger K, Zeindlhofe E, Gattermeier M, et al. Prospective comparison of flecainide versus sotalol for immediate cardioversion of atrial fibrillation. Am J Cardiol 1998; 81: 1450-1454.
25. Mabuchi N, Tsutamoto T, Maeda K, Kinoshita M. Plasma cardiac natriuretic peptides as biochemical markers of recurrence of atrial fibrillation in patients with mild congestive heart failure. Jpn Circ J 2000; 64: 765-771.
26. Flaker GC, Blackshear JL, McBride R, Kronmal RA, Halperin JL, Hart RG. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. J Am Coll Cardiol 1992; 20: 527-532.
27. Gallagher MM, Camm AJ. Classification of atrial fibrillation. Pacing Clin Electrophysiol 1997; 20: 1603-1605.
28. Falk RH, Knowlton AA, Bernard SA, Gottlieb NE, Battinelli NJ. Digoxin for converting recent-onset atrial fibrillation to sinus rhythm: A randomized double-blind trial. Ann Intern Med 1987; 106: 503-506.
29. Kinebuchi O, Mitamura H, Shiroshita-Takeshita A, Kurita Y, Ieda M, Ohashi N, et al. Oral verapamil attenuates the progression of pacing-induced electrical and mechanical remodeling of the atrium. Circ J 2004; 68: 494-500.
30. Oral H, Knight BP, Tada H, Ozaydin M, Chugh A, Hassan S, et al. Pulmonary vein isolation for paroxysmal and persistent atrial fibrillation. Circulation 2002; 105: 1077-1081.